Dermatologue FMH

Dermatologue FMH

     

    Dr Stéphane Kuenzli, dermatologue FMH


    Formation/Diplômes

    1999 Diplôme Suisse de médecin, Université de Genève, Suisse

    2004 Doctorat en médecine, Université de Genève, Suisse

    2004 Dermatologue FMH


    Formation postgraduée

    1999 Post-graduate Course in Experimental Medicine, Swiss National Science Foundation, faculty of medicine, university of Zurich, Zurich; Switzerland

    1999 Introductory Course on Laboratory Animal Science, institute of laboratory animal science of the university of Zurich, Switzerland

    1999-2001 Research fellow, département d?endocrinologie et diabètes, HUG, Genève

    1999-2000 Biostatistics course and elements of statistics for physicians; department de medicine et division d?informatique médicale, HUG, Genève

    2001-2003 Assistant et research fellow, department des neurosciences et dermatologie, Prof. J-H Saurat, HUG, Genève

    2003-2004 Chef de clinique, dermatologie, HUG, Genève


    Membre de sociétés professionnelles

    2000 Foederatio Medicorum Helviticorum (FMH)(Federation of Swiss Physicians)

    2004 Société suisse de dermatologie (SSDV)


    Présentations

    Kuenzli Stéphane, Lopez-Liuchi JV, Meier CA. Activation of PPAR by different kinase pathways. Division of Endocrinology, university Hospital of Zurich, Zurich; Switzerland. Mars 2000

    Lopez-Liuchi JV, Kuenzli Stéphane, Bonny C, Meier CA. Activation de PPAR par phosphorylation. Groupes de recherches en endocrinologie des universités de la région Rhônes-Alpes , Lausanne, Switzerland. April 2000

    Lopez-Liuchi JV, Kuenzli Stéphane, Feilchenfeldt J, Meier CA. Different signalling pathways activate the PPAR? in a cell specific manner. European Life Scientist Organisation, Geneva, Switzerland. September 2000

    Juge-Aubry CE, Kuenzli Stéphane, Sanchez JC, Hochstrasser D, Meier CA. A PPAR-regulated peroxisomal enzyme binds PPAR? and regulates its transcriptional activity. European Life Scientist Organisation, Geneva, Switzerland. September 2000

    S. Kuenzli; J. Perriard; G. Kaya; V. Piguet; P.-A. Piletta; J.-H. Saurat. Psoriasis and topical clofibrate. 2nd joint meeting international psoriasis symposium and European congress of psoriasis, june 19-24, 2001; San Francisco

    S.Kuenzli, Carreaux, JH Saurat. Topical PPAR and ligands in the mouse tail model and plaque psoriasis assay. ESDR, Geneva, September 2002

    S.Kuenzli, Carreaux, JH Saurat. Topical PPAR and ligands in the mouse tail model and plaque psoriasis assay; Psoriasis from gene to clinic, 3rd international congress, The Royal College of pysicians, London, 21-23 November 2002


    Bibliographie

    Juge-Aubry CE, Kuenzli S, Sanchez JC et al. Peroxisomal bifunctional enzyme binds and activates the activation function-1 region of the peroxisome proliferator-activated receptor alpha. Biochem J 2001; 353: 253-8.

    Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs 2001; 2: 625-30.

    Kuenzli S, Lübbe J. Acquisitions thérapeutiques 2001, dermatologie. Med Hyg.2002 ;60 :89-96

    Kuenzli S, Saurat J-H. Acquisitions thérapeutiques 2002, dermatologie. Med Hyg 2003 ;61 :113-116.

    Kuenzli S, Harms M. Interprétations des sérologies syphilitques: cas cliniques. Dermatologica Helvetica 2002 ; 3 :12-16

    Kuenzli S, Buchet S, Saurat J-H. Successful Treatment of Schnitzler?s Syndrome with Interferon Alfa-2b. Dermatology 2002: 205(1):74

    Kuenzli S, Saurat J-H. Traitement du lupus érythémateux chronique. Nouvelles dermatologiques. 2003 ;22 Suppl.1 :17-20.

    Kuenzli S, Saurat J-H. PPARs in cutaneous biology. British Journal of Dermatology. 2003, 149(2): 229-236.

    Kuenzli S, Saurat J-H. Topical PPAR b/d and PPAR g agonists on plaque psoriasis : a pilot study. Dermatology. 2003; 206(3):252-256

    Kuenzli S, Saurat J-H. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):205-11. Review.

    Kuenzli S, Grimaître M, Krischer J, Saurat J-H, Calza Am, Borradori L. Childhood bullous pemphigoid. Report of a case with life-threatening course during homeopathy treatment ". Pediatr Dermatol. 2004 Mar-Apr;21(2):160-3.

    Sorg O, Kuenzli S, Saurat J-H. Proposed mechanisms of action for retinoid derivatives in the treatment of skin aging. J Cosmet Dermatol. 2005 Dec;4(4):237-44.

    Kuenzli S, Tran C, Saurat J-H. Retinoid receptors in inflammatory responses: a potential target for pharmacology.Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):355-60. Review

    Barde C, Thielen AM, Kuenzli S, Saurat JH.Treatment of plaque psoriasis by sequential therapy with two 'biologics': the 'hit and run' approach, a report of two cases.Br J Dermatol. 2006 Jul;155(1):211-3. Review

    Kuenzli S, Thielen AM. Dermatology. Rev Med Suisse. 2005 Jan 12;1(2):119-22, 124. French.

    Kuenzli S, Saurat JH. Dermatology. Rev Med Suisse. 2006 Jan 11;2(48):107-8, 111-3. French.

    Kuenzli S, Saurat JH. Dermatology. Rev Med Suisse. 2007 Jan 17;3(94):128-31. Review. French.

    Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology. 2005;211(3):209-17. Review.

    Kuenzli S, Sorg O, Saurat JH.. Cyclopamine, hedgehog and psoriasis. Dermatology. 2004;209(2):81-3.


    Chapitres de livres

    Kuenzli S, Saurat J-H. Systemic retinoids in Dermatology in general medicine, 6th edition. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen, KF. McGraw-Hill Inc, 2003.

    Kuenzli S, Saurat J-H. Retinoids in Dermatology in Dermatology, 1st edition. Bolognia JL, Jorizzo JL and Rappini RP et al. Mosby, 2003.

    Kuenzli S, Saurat J-H. Retinoïdes in Dermatologie et maladies sexuellement transmissibles. Saurat J-H, Grosshans et al. Masson, 2004.


    Recherche clinique

    Kuenzli S, Saurat J-H. Efficacy and safety study of alitretinoin (BAL-4079) in the treatment of chronic hand dermatitis. Double-blind, randomized, placebo-controlled, parallel-group, dose-ranging, multicenter study. Basilea pharmaceutica, 2001-2002

    Kuenzli S, Saurat J-H. An open-label, multicenter study to evaluate the safety of repeat courses of intramuscular administration of alefacept in patients with chronic plaque psoriasis. Biogen, 2002-2003

    Kuenzli S, Thielen A-M, Janer V, Saurat J-H. A phase III, multicenter, randomized, double-blind, placebo-control trial evaluating the efficacy and safety of infliximab induction and maintenance therapy in patients with moderate to severre psoriasis. Express. Centocor. 2003-2005

    Kuenzli S, Thielen A-M, Saurat J-H. A multicenter, randomised, double-blind, placebo controlled phase III study of subcutaneously adminstrated Raptiva in the treatment of patients with moderate to severe plaque psoriasis. Serono. 2003-2005


    Organisation de congrès:

    Kuenzli S. and Saurat JH. Traitements du psoriasis: present et futur. Journée de printemps de la société suisse de dermatologie. Genève. 5 juin 2003.